MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC

Jiae Koh, Youjin Kim, Kyoung Young Lee, Joon Young Hur, Mi Soon Kim, Boram Kim, Hee Jin Cho, Yeong Chan Lee, Yeon Hee Bae, Bo Mi Ku, Jong Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

The major suppressive immune cells in tumor sites are myeloid derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and Treg cells, and the major roles of these suppressive immune cells include hindering T-cell activities and supporting tumor progression and survival. In this study, we analyzed the pattern of circulating MDSC subtypes in patients with non-small cell lung cancer (NSCLC) whether those suppressive immune cells hinder T-cell activities leading to poor clinical outcomes. First, we verified PMN-MDSCs, monocytic-MDSCs (M-MDSCs), and Treg cells increased according to the stages of NSCLC, and MDSCs effectively suppressed T-cell activities and induced T-cell exhaustion. The analysis of NSCLC patients treated with anti-PD-1 immunotherapy demonstrated that low PMN-MDSCs, M-MDSCs, and CD39+CD8+ T cells as an individual and all together were associated with longer progression free survival and overall survival, suggesting PMN-MDSCs, M-MDSCs, and CD39+CD8+ T cells frequencies in peripheral blood might be useful as potential predictive and prognostic biomarkers.

Original languageEnglish
Pages (from-to)1810-1819
Number of pages10
JournalEuropean Journal of Immunology
Volume50
Issue number11
DOIs
StatePublished - 1 Nov 2020

Keywords

  • CD39
  • IL-10
  • Immune checkpoint inhibitor
  • MDSC
  • Non-small cell lung cancer

Fingerprint

Dive into the research topics of 'MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC'. Together they form a unique fingerprint.

Cite this